Aclarubicin
Chemical compound
From Wikipedia, the free encyclopedia
Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer in China. It was previously approved for use in Europe but was discontinued in 2004 due to being rarely prescribed and unprofitable.
Legal status
- In general: ℞ (Prescription only)
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | IV |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.055.277 |
| Chemical and physical data | |
| Formula | C42H53NO15 |
| Molar mass | 811.878 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 151 to 153 °C (304 to 307 °F) (decomposes) |
| |
| |
| | |
However, it has subsequently been reevaluated[3] due to possible advantages over other chemotherapeutic drugs in the treatment of certain cancers such as acute myeloid leukemia.[4][5]
Soil bacteria Streptomyces galilaeus can produce aclarubicin.
It can induce histone eviction from chromatin upon intercalation.[6][7]